Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T94692
|
||||
| Former ID |
TTDR00225
|
||||
| Target Name |
Low-density lipoprotein receptor
|
||||
| Gene Name |
LDLR
|
||||
| Synonyms |
LDL receptor; LDLR
|
||||
| Target Type |
Successful
|
||||
| Disease | Non-small cell lung cancer [ICD10: C33-C34] | ||||
| Function |
Binds ldl, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits.
|
||||
| BioChemical Class |
LDLR family
|
||||
| UniProt ID | |||||
| Sequence |
MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQ
ETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGK CISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEW PQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDE FQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMAR DCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQD PDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYT SLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLA VDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPA KIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILE DEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQ PRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVA TQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGN EKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICH NQDGYSYPSRQMVSLEDDVA |
||||
| Structure |
1AJJ; 1D2J; 1F5Y; 1F8Z; 1HJ7; 1HZ8; 1I0U; 1IJQ; 1LDL; 1LDR; 1LRX; 1N7D; 1XFE; 2FCW; 2KRI; 2LGP; 2M7P; 2MG9; 2W2M; 2W2N; 2W2O; 2W2P; 2W2Q; 3BPS; 3GCW; 3GCX; 3M0C; 3P5B; 3P5C; 3SO6; 4NE9
|
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Porfimer Sodium | Drug Info | Approved | Non-small cell lung cancer | [1] |
| Inhibitor | Alpha-D-Mannose | Drug Info | [2] | ||
| Modulator | Porfimer Sodium | Drug Info | [3] | ||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| KEGG Pathway | Endocytosis | ||||
| Ovarian steroidogenesis | |||||
| Bile secretion | |||||
| Toxoplasmosis | |||||
| Hepatitis C | |||||
| NetPath Pathway | FSH Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| Reactome | LDL-mediated lipid transport | ||||
| Chylomicron-mediated lipid transport | |||||
| Retinoid metabolism and transport | |||||
| WikiPathways | DNA Damage Response (only ATM dependent) | ||||
| Statin Pathway | |||||
| Wnt Signaling Pathway | |||||
| Wnt Signaling Pathway and Pluripotency | |||||
| Visual phototransduction | |||||
| Lipid digestion, mobilization, and transport | |||||
| Oncostatin M Signaling Pathway | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| SREBP signalling | |||||
| Folate Metabolism | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.